Most of the volume in GBR over the past year has gone through at...

Most of the volume in GBR over the past year has gone through at higher prices and the average weighted buy price of the "freely tradeable stock" since November last year to now, is still above $0.40. Trading at these lower levels is relatively light in comparison and probably a bargain for new holders. The stock is very tight, if your GBR shareholding has a cost base below $0.40 you are either in the top 20, part of management or in the small minority.

Understandably, a few holders are becoming disillusioned due to lack of news, which is a little overdue in my opinion. However, apparently management have a policy to report on assays only and ignore the visuals and handheld analysis.

I would say that by now they should have enough assays to provide an update and as Happy Trader says, news should be imminent.

I'm not expecting a block buster announcement just yet but do think it will be better than what the market expects.